AB Klaipėdos Nafta preliminary activity and revenue

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
40
AB Klaipėdos Nafta preliminary activity and revenue results for the March 2019

In March 2019 AB Klaipėdos nafta (hereinafter – the Company or KN) has reloaded 461 thousand tons of petroleum products in Klaipėda and Subačius oil terminals. In 2018 reloaded 599 thousand tons (less by 23.0 per cent).

During the first three months of 2019 the Company in total reloaded 1,541 thousand tons of petroleum products into its storage tanks or less by 24.5 per cent compared to the same period of 2018 when 2,039 thousand tons were reloaded. The overall decrease in loading volumes for the three months mainly were affected by the lower quantities from ORLEN Lietuva refinery and by the lower transshipment quantities of heavy oil products transit.

The preliminary sales revenue of the Company’s oil terminals for March 2019 reached EUR 2.6 million. The preliminary sales revenue for January – March 2019 of the Company’s oil terminals comprise EUR 8.2 million (during the same period of 2018 - EUR 11.2 million).

In March 2019 the Company’s Liquefied Natural Gas (LNG) terminals have re-gasified and reloaded 96 thousand MWh of natural gas, comparing to the same period of 2018 (509 thousand MWh) it is less by 81.1 per cent. In the second part of February LNG regasification had been temporary stopped due to the maintenance of LNG terminal. Re-gasification started from the end of March. During the first three months of 2019 the Company in total re-gasified and reloaded 740 thousand MWh of the natural gas (during the same period of 2018 – 1,100 thousand MWh).

The preliminary sales revenue of the Company’s LNG Terminal for March 2019 comprised EUR 5.6 million (during the same period of 2018 – EUR 4.7 million). Revenue consists of the re-gasification tariff fixed part (for booked annual capacities) and variable part for amount of re-gasified LNG as well as and reloading tariffs. The preliminary revenue of the LNG terminal for the first three months of 2019 comprise EUR 18.1 million and are higher by 9.0 per cent compared to the same period of 2018 (EUR 16.6 million).

Total preliminary sales revenue of the Company in January - March of 2019 amount to EUR 26.3 million, or less by 5.4 per cent compared to the same period of 2018 - EUR 27.8 million.

Petroleum products transshipment and LNG re-gasification and reloading:

  March January - March
  2019 2018 Change, % 2019 2018 Change, %
Petroleum products reloaded, thousand tons 461 599 -23.0% 1,541 2,039 -24.5%
LNG re-gasification and reloading, thousand MWh 96 509 -81.1% 740 1,100 -32.7%

Petroleum products transshipment, LNG re-gasification and reloading volumes in 2019:

  January February March
Petroleum products reloaded, thousand tons 626 454 461
LNG re-gasification and reloading, thousand MWh 471 173 96

Preliminary revenue of the Company, EUR million:

  March January - March
  2019 2018 Change, % 2019 2018 Change, %
Oil terminals’ activity 2.6 3.4 -23.5% 8.2 11.2 -26.8%
LNG terminal activity 5.6 4.7 19.1% 18.1 16.6 9.0%
Total: 8.2 8.1 1.2% 26.3 27.8 -5.4%

   Jonas Lenkšas, Chief Financial Officer, +370 694 80594

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading